Mandate

Vinge advises Wilson Therapeutics in connection with directed share issue

December 12, 2017

Vinge has advised Wilson Therapeutics on a directed new issue of shares, whereby Wilson Therapeutics raises proceeds of approximately SEK 244 million, before issue costs.

The share issue is directed to a number of selected institutions and sector specialist funds, internationally and in Sweden, on the basis of an accelerated bookbuilding process.

Vinge’s team consisted of Christian Lindhé, Erik Sjöman, Mattias Sköld, Ludvig Frithiof and Astrid Karlsson.

Related

Vinge advises Sertion in connection with the acquisition of Kiefer System Group

Vinge has advised Sertion AB (“Sertion”) in connection with the acquisition of Kiefer System Group.
October 10, 2025

Vinge advises Main Capital and Aritma in connection with the acquisition of Programekonomi

Vinge has advised Aritma International AS (“Aritma”), a Norwegian bank-connectivity and financial automation software provider, in connection with the acquisition of Programekonomi Svenska Aktiebolag.
October 09, 2025

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025